An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
This open-label, multicenter study evaluated the efficacy, safety, and cycle control of Yasmin, a new low-dose, monophasic oral contraceptive containing the unique progestogen drospirenone (DRSP) 3 mg and ethinyl estradiol (EE) 30 microg. DRSP is a synthetic progestogen that has antiandrogenic and antimineralocorticoid effects. In this study, 326 women were evaluated and 220 (67%) completed all 13 treatment cycles. The corrected Pearl Index was 0. 407. Of the 151 subjects who experienced intermenstrual bleeding at any time during the study, the majority (64%) had bleeding during only one or two pill cycles. Breakthrough bleeding without spotting occurred in 1% of all cycles, spotting without breakthrough bleeding in 9.3% of all cycles, and breakthrough bleeding with spotting in 3% of all cycles. Amenorrhea was observed in 3% of all cycles. In all, 20 subjects (6%) discontinued participation in the study because of adverse events. No serious adverse events related to the study drug were reported. No clinically significant changes in weight, blood pressure, or lipids were reported. The impact of the new progestogen DRSP on the women's self-perception of menstrual health was also evaluated. Subjects reported that symptoms of water retention, negative affect, and increased appetite significantly improved at cycle 6 from baseline. This study demonstrates that Yasmin is an effective oral contraceptive that is safe and well tolerated.
Parsey
K S
KS
Berlex Laboratories, Montville, New Jersey 07045-1000, USA.
Pong
A
A
D000293:Adolescent; D000328:Adult; D000736:Androstenes / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use; D001794:Blood Pressure; D001835:Body Weight; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008599:Menstruation Disturbances / Q000139:chemically induced; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use; D010349:Patient Compliance; D045167:Progesterone Congeners / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D014592:Uterine Hemorrhage / Q000139:chemically induced
D000736:Androstenes; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D008055:Lipids; D000451:Mineralocorticoid Receptor Antagonists; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; C035144:drospirenone